Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ICT-107 · 1 trial · 1 indication
The objective is to compare overall survival (OS) in patients when treated with ICT 107 versus Control. OS defined as the time from randomization until date of death or the last date patient known alive (if death is not observed) All randomized patients are included in Intent to Treat analysis
Overall survival in a predefined subpopulation. All randomized patients are included in intent to treat analysis.
| Arm | Type | Description |
|---|---|---|
| ICT-107 | EXPERIMENTAL | Autologous dendritic cells pulsed with immunogenic peptides from tumor antigens |
| Control | PLACEBO_COMPARATOR | Autologous dendritic cells that have not been pulsed with antigens |
| Name | Type | Description |
|---|---|---|
| ICT-107 | BIOLOGICAL | Autologous dendritic cells pulsed with immunogenic antigens |
| Placebo DC | BIOLOGICAL | Autologous dendritic cells (DC) that have not been pulsed with antigens |
Inclusion Criteria: 1. Confirmed, initial diagnosis of GBM. Patients must be newly diagnosed with GBM and not yet received chemoradiation. 2. ≥ 18 years of age 3. HLA-A1 or HLA-A2 positive 4. KPS score of ≥ 70% 5. Baseline hematologic studies and chemistry profiles must meet the following criteria:...
ICT-107 is an investigational immunotherapy being studied for the treatment of Glioblastoma Multiforme (GBM), a type of brain cancer. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
ICT-107 is a monoclonal antibody designed to target tumor-associated antigens in Glioblastoma Multiforme. It is being developed as an immunotherapy to stimulate the patient's immune system against cancer cells.
ICT-107 is being developed by Precision BioSciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol DTIL.
ICT-107 is currently in Phase 2 clinical development. It has completed one Phase 2 trial and is not yet approved for commercial use.
ICT-107 has been studied in a Phase 2 clinical trial with the identifier NCT01280552. This trial, titled 'A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)', was completed and enrolled 124 participants in the United States.
ICT-107 is the primary name for this investigational drug. No alternative names have been reported for this asset.